Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

CTXR

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CTXR
DateTimeSourceHeadlineSymbolCompany
05/29/20248:30AMPR Newswire (US)Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
05/21/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
05/21/20247:00AMPR Newswire (US)Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
05/14/20244:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
05/14/20244:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
05/14/20244:05PMPR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
05/10/20248:30AMPR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
04/30/20244:05PMPR Newswire (US)Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
04/26/20248:00AMPR Newswire (US)Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
04/11/20248:30AMPR Newswire (US)Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
04/04/20248:30AMPR Newswire (US)Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceNASDAQ:CTXRCitius Pharmaceuticals Inc
03/18/20248:30AMPR Newswire (US)Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
03/07/20248:30AMPR Newswire (US)Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramNASDAQ:CTXRCitius Pharmaceuticals Inc
03/04/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTXRCitius Pharmaceuticals Inc
02/26/20247:30AMPR Newswire (US)Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationNASDAQ:CTXRCitius Pharmaceuticals Inc
02/23/20244:23PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CTXRCitius Pharmaceuticals Inc
02/23/20244:18PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTXRCitius Pharmaceuticals Inc
02/23/20248:30AMPR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
02/15/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
02/14/20244:40PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
02/14/20244:30PMPR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
02/14/20249:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
02/14/20248:01AMPR Newswire (US)Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIRâ„¢ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
01/26/20244:15PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CTXRCitius Pharmaceuticals Inc
01/26/20244:08PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CTXRCitius Pharmaceuticals Inc
01/26/20244:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
01/23/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
01/23/20248:30AMPR Newswire (US)Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsNASDAQ:CTXRCitius Pharmaceuticals Inc
01/05/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
01/02/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CTXR